C. Ringer Healthcare Unveils The Dilutions Premiere 2026, Expands Its Homeopathic Product Portfolio

C. Ringer Healthcare Private Limited marked a new chapter in its healthcare journey with The Dilutions Premiere 2026, showcasing an extensive portfolio of homeopathic dilutions aimed at addressing a range of commonly encountered health and wellness concerns.

The event was attended by Dr. Rani Banerjee, Managing Director & CEO, C. Ringer Healthcare Private Limited, and Dr. Lokesh Kumar Pradhan, along with members of the healthcare and industry community. The showcased portfolio featured 157 medicines, available across different dilution strengths and pack sizes. The range included widely known homeopathic preparations such as Arnica Montana, traditionally associated with bruising and muscular soreness; Allium Cepa, commonly used in homeopathic practice for symptoms resembling a runny nose and watery eyes; Nux Vomica, traditionally associated with digestive discomfort; and Aconitum Napellus, associated in homeopathic practice with sudden-onset cold and fever-like symptoms. Other formulations on display included Belladonna, Bryonia, Calendula, Chamomilla, Gelsemium, Phosphorus, Rhus Toxicodendron, Silicea and Sulphur, which are traditionally used by homeopathic practitioners for different symptom profiles.

Speaking on the occasion, Dr. Rani Banerjee, Managing Director & CEO, C. Ringer Health Care Private Limited, said, “Our journey has been shaped by a legacy that spans generations. With The Dilutions Premiere 2026, we are taking that legacy forward into a new era of healthcare. Our endeavour is to bring together the trust associated with our heritage and the evolving needs of today’s consumers.” The launch reflected C. Ringer Healthcare’s endeavour to build on its longstanding heritage while expanding its product portfolio and responding to evolving consumer requirements in the healthcare sector.